s6y

Sionna Therapeutics, Inc.

Ticker
SION
CIK
2036042
Industry
Pharmaceutical Preparations

Financials 8

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024

News 14

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 14 news filings

Ownership 100

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 100 ownership filings

Prospectus 10

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
  3. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  4. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  5. S-1MEF A new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-1
  6. S-1/A General form of registration statement for all companies including face-amount certificate companies
  7. S-1 General form of registration statement for all companies including face-amount certificate companies
  8. DRSLTR Correspondence Related to Draft Registration Statement
  9. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  10. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Proxies 4

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements

Other 98

  1. SCHEDULE 13G
  2. SCHEDULE 13D/A
  3. 144 Filing for proposed sale of securities under Rule 144
  4. 144 Filing for proposed sale of securities under Rule 144
  5. 144/A Filing for proposed sale of securities under Rule 144
  6. 144 Filing for proposed sale of securities under Rule 144
  7. SCHEDULE 13G/A
  8. SCHEDULE 13G/A
  9. ARS Annual report to security holders
  10. SCHEDULE 13D/A

All 98 other filings